Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Shijie Ren, Hazel Squires, Emma Hock, Eva Kaltenthaler, Andrew Rawdin & Constantine Alifrangis

The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal

Edward Cox, Ros Wade, Mathilde Peron, Kristina Charlotte Dietz, Alison Eastwood, Stephen Palmer & Susan Griffin

Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions

Marina Treskova, Stefan M. Scholz & Alexander Kuhlmann

Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations

Mario J. N. M. Ouwens, Pralay Mukhopadhyay, Yiduo Zhang, Min Huang, Nicholas Latimer & Andrew Briggs

Mapping the PedsQL™ onto the CHU9D: An Assessment of External Validity in a Large Community-Based Sample

Christine Mpundu-Kaambwa, Gang Chen, Elisabeth Huynh, Remo Russo & Julie Ratcliffe

Severity-Adjusted Probability of Being Cost Effective

Matthijs M. Versteegh, Isaac Corro Ramos, Nasuh C. Buyukkaramikli, Amir Ansaripour, Vivian T. Reckers-Droog & Werner B. F. Brouwer

Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe

Dominik Golicki, Michał Jakubczyk, Katarzyna Graczyk & Maciej Niewada

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States

Thomas E. Delea, Xinke Zhang, Jordan Amdahl, Diana Boyko, Franziska Dirnberger, Marco Campioni & Ze Cong